G lioblastoma is the most common and most malignant primary brain tumor in adults. It accounts for more than 50% of glial neoplasms and usually presents in the 6th or 7th decade of life. The incidence in Europe and North America is 2-3 cases per 100,000 people per year. 4, 22 Despite modern therapy including microsurgical resection, as well as adjuvant radiation therapy and chemotherapy, 75% of patients with glioblastoma die within 18 months after diagnosis. 22 The standard treatment includes microsurgical resection, postoperative external beam radiation therapy with a total dose of 54-60 Gy, and different protocols of chemotherapy. 9, 11, 12, 25, 30, 33 Many predictive factors have been considered in glioblastoma patients. Good neurological status, extent of resection, and young age have been reported to correlate with longer survival. 9, 11 In particular, the importance of the extent of resection as a prognostic factor has been demonstrated in several studies. 23, 29, 31 One of the most important prognostic factors that is widely accepted is younger patient age. 16 However, the number of elderly patients with glioblastoma is increasing, as the elderly population is growing. Treatment options in elderly patients with glioblastoma are poorly defined and described. Cancer therapy trials frequently exclude elderly patients, based on the argument that these patients do not tolerate adjuvant therapies as well as younger patients. 6 Results of several studies suggest that older age leads to discussion as to whether any therapy, either operative or adjuvant treatment, should be performed; thus, elderly patients do not receive standard therapy. 6, 14, 18, 20 Some authors even state that elderly patients are frequently treated suboptimally or that further therapy is often based on ad hoc decisions made by physicians. 5, 7 However, the threshold of age as a predictive factor, and if so which age, remains to be defined. 1, 15, 26 The aim of the present study was to present a large current series of patients with newly diagnosed and untreated glioblastomas, comparing survival times in younger and elderly patients. In this single-institution series, all patients were treated with aggressive multimodality treatment initially and at recurrence, regardless of patient age.
Methods

Study Population
The data derive from a large prospectively collected database of patients with cerebral gliomas who underwent regular follow-up examinations from the initial diagnosis to eventual death. In this study, a total of 361 consecutive patients with newly diagnosed and untreated malignant WHO Grade IV cerebral gliomas from 2000 to 2006 were analyzed. Diagnosis of WHO Grade IV glioma was confirmed by independent histopathological examination in all patients. The choice of surgical treatment (biopsy or resection) depended on tumor size, tumor location/eloquence, and general patient condition, but not on patient age. The general condition of patients was based on the KPS score, comorbidities, and neurological status.
Patient Groups
For further analysis, patients were divided into age groups at the time of diagnosis. Patients 65 years of age and older were defined as "elderly," whereas the remaining patients were defined as "younger" patients. The cutoff chosen at 65 years in the age groups was based on common inclusion criteria in cancer therapy trials, which exclude patients older than 65 years of age.
Patients were further divided into a biopsy or a resection group, according to the surgical procedure performed. In the resection group, we further subdivided between complete, subtotal, and partial resection. The extent of resection was defined according to early postoperative MR imaging (within 72 hours following surgery) after interpretation of imaging data by independent, experienced neuroradiologists. If no residual contrast enhancement was observed, the resection was defined as complete. Resection was defined as subtotal if residual contrast-enhancing tissue accounting for less than 5% of preoperative tumor volume was present. In all other cases, the resection was defined as partial.
All patients received adjuvant treatment consisting of radiation therapy, chemotherapy, or combined radiation and chemotherapy. Radiation therapy was performed using 56-60 Gy. Before combined radiation and chemotherapy with temozolomide 30 was implemented, some patients received nimustine hydrochloride 27 combined radiation and chemotherapy. In cases of tumor recurrence, all treatment options were reevaluated regardless of age.
Statistical Analysis
Statistical analyses were performed with commercially available software (SPSS version 13, Graph Pad InStat version 3.06). Dichotomous data were assessed using the chi-square or Fisher exact test. Survival was evaluated using Kaplan-Meier estimates. Differences in survival were assessed using the unpaired t-test with the Welch correction and Kruskal-Wallis test. Factors potentially influencing survival were assessed in a multivariate analysis using the Cox proportional hazards model. Variables that were included in this model were patient age, KPS score, sex, adjuvant therapies, surgical therapy (biopsy vs resection), and the extent of resection. Probability values < 0.05 were considered statistically significant.
Results
Patient Characteristics
Of 361 patients, 146 (40.4%) were ≥ 65 years old at first diagnosis and treatment and comprised the group of elderly patients (Table 1) . In this group, median age was 70 years (range 65-84 years). Two hundred fifteen (59.6%) were < 65 years old and comprised the younger patient group with a median age of 57 years (range 17-64 years).
There was a slight preponderance of male patients (59%) in the overall study population. There were more male patients in the younger group than in the elderly group (63% vs 53%, respectively), but this difference did not quite reach statistical significance (p = 0.06, OR 0.7, 95% CI 0.4-1.0).
Of the 361 patients, 234 (65%) underwent resection and 127 (35%) underwent biopsy. In the younger group, significantly fewer patients underwent biopsy compared with the elderly patients (p = 0.001, OR 0.7, 95% CI 0.5-0.8). Within the resection group, comparing the extent of resection between the age groups revealed no significant differences.
Tumor characteristics, such as tumor location and tumor volume, are described in Table 2 in detail. We found no statistically significant difference in preoperative tumor volumes between elderly and younger patients. Regarding tumor location, there was a significantly greater number of tumors located in the Broca and Wernicke areas in the elderly patients and a significantly greater number of tumors located in the parietal lobe in the younger patients. In all other tumor locations, no statistically significant difference between elderly and younger patients was found.
Elderly patients had statistically significantly lower preoperative KPS scores than younger patients in both the biopsy and the resection group (Table 3) .
Additional medical conditions that independently influenced the surgical decision were found in 8 cases. Within the younger age group, 1 (0.5%) of 215 patients (previous fulminant pulmonary embolism) and, in the older group, 7 (5%) of 146 patients underwent biopsy due to a medical condition (p = 0.009).
Progression-Free Survival
As of September 2008, 341 of 361 patients had developed tumor progression. Kaplan-Meier analysis rendered a median overall PFS of 8.9 months for all patients included in this study (Table 4 ). Overall PFS of elderly patients was 7.5 months compared with 9.7 months in younger patients (p = 0.1; Fig. 1 ). Furthermore, we analyzed the resection and biopsy groups, comparing the two age groups, as well as the subgroups of resection (partial, subtotal, and complete). There was no significant difference between the age groups concerning PFS (Fig. 1) .
In addition, we analyzed PFS within the age groups, comparing the extent of resection and biopsy (Table 5) . There were significant differences in PFS between the resection and biopsy group in both the elderly and younger patients, as well as between partial and complete resection in the younger patients. Surprisingly, a significant difference in PFS when comparing complete and subtotal resection was only found in younger patients (p = 0.007). No significant difference in PFS was found in either age group comparing subtotal and partial resection.
Overall Survival
As of September 2008, 304 of 361 patients had died. Kaplan-Meier analysis rendered a median overall survival of 11.6 months for all patients included in this study (Table 6 ). Overall survival of elderly patients was 9.1 months compared with 14.9 months in younger patients (p = 0.0001; Fig. 2 ). However, the influence of age differed between the subgroups of patients undergoing biopsy, partial resection, and subtotal resection. Furthermore, we analyzed the subgroups in regard to operative treatment (complete, subtotal, and partial resection, or biopsy) and survival time (Fig. 3) .
Analyzing the influence of surgical treatment on the overall survival of all patients showed a significant difference between all subgroups of resection and biopsy (complete, subtotal, and partial resection vs biopsy; p < 0.0001). However, comparing the subgroups of resection, only subtotal versus partial resection had a significant difference on overall survival of all patients (Table 5) .
In the elderly patients with glioblastoma undergoing resection, median survival was 13.0 months compared with 13.3 months in the younger group (p = 0.86; Table 6 ). Survival time in patients with complete resection was 17.7 months in the elderly and 16.5 months in the younger patients (p = 0.68). In patients with subtotal resection, survival time was 16.1 months in the elderly and 15 months in the younger patients (p = 0.65). Patients with partial resection had a median survival of 11.4 months in the elderly group versus 13.3 months in the younger patients (p = 0.27). No significant differences between the elderly and the younger patients could be found in any resection subgroup (complete, subtotal, or partial).
Operative Treatment
Within the elderly group, we found no significant difference (p = 0.55) in survival time between those undergoing complete (17.7 months) and subtotal resection (16.1 months; Table 7 ). No significant difference (p = 0.57) in survival time was found in the younger group for complete (16.5 months) and subtotal resection (15.0 months).
Within the elderly group, we found a significant dif- A significant difference in survival time (p = 0.03) was found among the elderly patients when comparing subtotal (16.1 months) and partial resection (11.4 months). However, no significant difference (p = 0.33) was found in the younger group for these two variables (15.0 and 13.3 months, respectively).
In the group of elderly patients undergoing resection of any extent, survival time was 13.0 months compared with 4 months in the biopsy group (p < 0.0001). In younger patients, survival time was 13.3 months in the group with any type of resection compared with 7.9 months in the biopsy group (p = 0.0071).
The biopsy group is the only subgroup that showed significant differences between the elderly and the younger patients. Comparing survival time within the age groups undergoing biopsy showed that elderly patients had a median survival time of 4 months compared with a median survival time of 7.9 months in the younger patients (p = 0.007; Table 7 ).
Postoperative Treatment
No significant differences in postoperative treatment strategies were found when comparing the elderly to the younger patients (radiation therapy 43% vs 43%, respectively, p = 1.00; combined radiation and chemotherapy treatment 40% vs 47%, respectively, p = 0.23; and no adjuvant therapy 17% vs 11%, respectively, p = 0.08; Table  8 ). There were no significant differences between the age groups in the intensity and toxicity of adjuvant therapy (radiation p = 1.0, OR 0.97, 95% CI 0.16-5.99; radiation and chemotherapy p = 0.80, OR 1.17, 95% CI 0.45-3.06; Table 9 ).
Sex Differences
Comparing sexes in both age groups revealed no significant differences in survival. Only in the younger group, a comparison of men to women in the biopsy subgroup showed significant longer survival times (men 6.7 months vs women 11.7 months) favoring the women (p = 0.03). In a comparison of men to women within each age group, elderly patients showed no significant difference in survival time.
Multivariate Analysis
All variables of the univariate analyses were tested in a multivariate regression model. In the resection group, the variable that remained significant for longer survival was female sex (OR 1.5, 95% CI 1.1-2.2, p = 0.02), and the variable significant for shorter survival was no adjuvant therapies (OR 0.2, 95% CI 0.07-0.3, p < 0.001). In the biopsy group, the variables influencing the survival time in the univariate analyses that remained significant in the Cox regression were age older than 65 years (OR 0.3, 95% CI 0.2-0.5, p < 0.001) and no adjuvant therapies (OR 0.2, CI 0.1-0.4, p < 0.001) for shorter survival, and KPS score ≥ 70 (OR 2.2, 95% CI 1.1-4.3, p = 0.03) for longer survival.
In addition, we tested survival within the resection groups with a Cox regression model, which revealed HRs < 1 in the elderly patients with complete (HR 0.6, 95% CI 0.5-0.9), subtotal (HR 0.8, 95% CI 0.6-1.2), or partial (HR 0.9, 95% CI 0.7-1.3) resections (Table 10) . Only the biopsy group showed an HR > 1 (1.9, 95% CI 1.4-2.6) in the elderly group. 
Discussion
Gliomas are the most common primary brain tumors in adults, and the most frequent (glioblastoma) is the most malignant. 22 Many cancer therapy trials have tested various treatment modalities in glioblastoma therapy in individuals younger than 65 years of age. 28, 30, 32 However, treatment strategies are only established for younger patients, and there are sparse data concerning elderly patients and optimum treatment strategies. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] 26 In many cancer therapy trials, one of the exclusion criteria is age greater than 65 years. However, the general population is becoming older, and the number of elderly patients with glioblastoma is also increasing, 7, 10, 20 as our study confirmed, with 40% of our patients with glioblastoma being older than 65 years. Often elderly patients do not receive multimodal therapies because of the widely held belief that elderly individuals do not tolerate chemotherapy and/ or radiotherapy as well as younger patients. In fact, many studies have shown that old age is one of the predictive factors for poor outcome in patients with malignant glioma. 17, 22, 28, 30, 32 The question that remains is whether age only influences the outcome (overall survival and PFS) due to different treatments offered to elderly patients or whether elderly patients with glioblastoma cannot tolerate the same aggressive treatment as younger patients.
In this single-center study, the decision to proceed with a specific surgical treatment was based on tumor location and eloquence and general patient condition. At our institution, patients were treated with surgery (resection or biopsy) followed by radiotherapy or a combination of radiation therapy and chemotherapy. Standard of care treatment as established in recent studies 29, 30 was offered to all patients with glioblastoma. As other authors have already described, age appears to influence decisionmaking in patients with glioblastoma prior to other criteria and leads to no or fewer treatment options offered to elderly patients. Authors of the Minnesota cohort study 20 (139 patients with glioblastoma, > 65 years old) showed that elderly patients are significantly more likely to receive no treatment or have fewer therapy options offered to them than younger patients. Biopsy and radiation therapy are more likely to be offered to elderly individuals than resection and multimodal therapy. 2 In the Glioma Outcomes Project 10 (418 individuals with glioblastoma, 48% > 60 years old), the authors found a longer median survival for patients treated at academic institutions using multimodal treatment options. They also stated that younger patients were mostly treated in academic institutions, and elderly patients received less treatment in small nonacademic institutions. 10 This indicates that elderly patients commonly receive less aggressive treatment than younger patients. Old age frequently is the only determining factor for less invasive and less aggressive treatment.
Although a matter of scientific dispute, it is becoming increasingly evident that the extent of resection is one of the strongest prognostic factors in the survival of glioblastoma. 13, 23, 29, 31 Those studies concerning the extent of resection are based on cancer therapy trials, again excluding patients older than 65 years. These studies cannot answer the question of whether the extent of resection is also one of the dependent factors in elderly patients. In our series, surgical therapy and the extent of resection were statistically significant prognostic factors in both elderly and younger patients concerning PFS and overall survival.
This study represents the largest series addressing PFS and overall survival of elderly patients with glioblastoma to date. We demonstrated for the first time that there is no significant difference in PFS and survival between elderly and younger patients in the subgroup of patients undergoing tumor resection. The PFS did not differ at all within the age groups. Overall survival was significantly worse for the elderly only in the biopsy group compared with the younger patients. Within the elderly group, a significantly greater number of patients underwent biopsy compared with the younger patients. One explanation for this difference could be the higher rate of patients with eloquently located tumors (in the Wernicke or Broca areas) among the elderly patients. These tumor locations lead to a higher rate of elderly patients undergoing biopsy compared with younger patients. Another reason for the higher number of biopsies within the elderly group might be the significantly lower preoperative KPS score for patients older than 65 years compared with the younger patients. Furthermore, a greater number of patients underwent biopsy due to medical conditions in the elderly group compared with the younger group. In general, comorbidities are more often present in older patients than in younger ones.
Addressing the extent of resection, we found significant differences in survival time in elderly patients. Partial resection (11.4 months) was associated with significantly shorter survival compared with complete (17.7 months) or 48 (13) 25 (17) 23 (11) 0.08 resection 20 11 (7) 9 (4) biopsy 28 14 (10) 14 (7) * chemo = chemotherapy.
subtotal (16.1 months) resection. This observation was not made in younger patients. Comparing our study with others, we found differences in overall survival time. McGirt et al. 21 showed a median survival of 13 months in patients with complete resection compared with 16.5 months in our study. Likewise, in the series of McGirt et al., survival in patients with partial resection was lower (8 vs 13.3 months, respectively). Stummer et al. 29 reported a median survival of 16.7 months after complete resection and 11.8 months after partial tumor resection. In our series of patients younger than 65 years undergoing partial resection, median survival was 13.3 months. One explanation for no significant difference in survival time when comparing the grade of resection in the younger patients could be the longer survival time of patients with partial resection in our study compared with the results of McGirt et al. and Stummer et al.
We were able to show that, regardless of age, predictive factors of longer survival time are the extent of resection and the preoperative KPS score. Therefore, the same criteria for operative treatment decisions should be applied to all patients. In this study, we could show that there were no differences in adjuvant therapies between the age groups, and there were no differences in toxicity of adjuvant therapies. The impact of adjuvant therapy on survival time is an important variable in addition to the extent of resection. Elderly patients can tolerate the same aggressive treatment as younger ones.
Patients in our study underwent regular follow-up evaluations at 3-month intervals and received supportive therapy in addition to multimodal treatment strategies. Good supportive therapy is needed in all patients with glioma, as shown in different studies. 3 Morbidity and mortality are greatly increased in patients suffering from brain edema, seizures, venous thromboembolism, and cognitive dysfunction, which can be recognized and treated early in patients who have regular visits and receive supportive treatment. 3, 19 Decision-making concerning therapeutic strategies at first presentation and at recurrence was based on interdisciplinary discussions among neurosurgeons, radiotherapists, and neurooncologists. Decisions were made according to tumor size, tumor location/eloquence, and general patient condition. The general condition of patients was based on the KPS score, comorbidities, and neurological status.
The limitations of our patient series are the retrospective nature of the series and a selection bias that cannot be ruled out in a retrospective study. Also, the greater number of elderly patients undergoing biopsy could be a possible selection bias, but one must consider that comorbidities and worse general conditions are more likely to be found in elderly patients. In the future, cancer therapy trials might need to widen the range of acceptable patient ages as inclusion criteria to avoid some of the limitations of this study.
Conclusions
In this patient series, patient age did not play a role in the decision-making process. We suggest that elderly patients be treated using the same standard therapy as younger patients. Our results demonstrate that treatment decisions in elderly patients with glioblastoma can be based on tumor size, tumor location/eloquence, and general patient condition. If these criteria are met, patients older than 65 years of age can tolerate the same aggressive treatment modalities as younger patients. Furthermore, there is no difference in outcome (PFS and overall survival) in the resection group when comparing the 2 age groups. Aggressive treatment of all patients with glioblastoma depending only on tumor location and general condition is warranted. Older age, per se, should not lead to an exclusion of patients with glioblastoma from extensive surgery or multimodal adjuvant treatment.
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